These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36074149)

  • 1. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
    Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
    Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
    Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR
    Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging diagnosis and efficacy monitoring by [
    He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
    Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.
    Chevaleyre C; Novell A; Tournier N; Dauba A; Dubois S; Kereselidze D; Selingue E; Jego B; Maillère B; Larrat B; Nozach H; Truillet C
    Theranostics; 2023; 13(15):5584-5596. PubMed ID: 37908736
    [No Abstract]   [Full Text] [Related]  

  • 8. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Chelator-to-Antibody Ratio on Development of
    Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated radiosynthesis of [
    Wichmann CW; Poniger S; Guo N; Roselt P; Rudd SE; Donnelly PS; Blyth B; Van Zuylekom J; Rigopoulos A; Burvenich IJG; Morandeau L; Mohamed S; Nowak AK; Hegi-Johnson F; MacManus M; Scott AM
    Nucl Med Biol; 2023; 120-121():108351. PubMed ID: 37224789
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
    J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
    Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET.
    Ibrahim D; Simó C; Brown EL; Shmuel S; Panikar SS; Benton A; DeWeerd R; Dehdashti F; Park H; Pereira PMR
    Front Immunol; 2024; 15():1405485. PubMed ID: 38915392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.